“Curaleaf’s Revised Offer Still Does Not Reflect the Value”: Aurora Rejects $5 Hostile Bid

In an October 14 statement, Aurora’s board reaffirmed its recommendation that shareholders reject Curaleaf’s revised hostile bid, which raises the maximum consideration to $5 per Aurora share, up from the previous $4 ceiling.

The revised offer includes $1 in cash and Curaleaf shares, with the stock component representing approximately 80% of the stated consideration.

“Curaleaf’s revised offer still does not reflect the value of the company Aurora shareholders own today,” said Miguel Martin, Aurora’s executive chairman and CEO.

“Aurora is debt-free with a strong cash position, and we believe the revised Hostile Bid continues to ask shareholders to give up that strength, and their future upside, at a discount,” Martin added.

Why Aurora Said No

Aurora outlined several objections to the revised proposal.

First, the company argues that Curaleaf would effectively use Aurora’s own cash reserves to help finance the acquisition. Its financial advisor also issued an updated opinion concluding that the consideration remains inadequate.

Second, Aurora warned that shareholders would assume substantial exposure to Curaleaf’s share price. While the offer caps potential proceeds at $5 per Aurora share, its stock-heavy structure leaves shareholders exposed to declines in Curaleaf’s valuation.

The board also questioned Curaleaf’s projected merger synergies, arguing that the estimated savings have not been adequately supported and that most of the potential benefits would accrue to existing Curaleaf shareholders.

Finally, Aurora believes the proposal fails to account for its international medical cannabis business, debt-free balance sheet and future earnings potential.

Aurora Is Exploring Alternatives

The company confirmed that its special committee is actively evaluating strategic alternatives, potentially including competing transactions.

“Curaleaf’s offer remains open until December 4, 2026, so we believe shareholders gain nothing by tendering now,” Martin said.

Aurora warned that accepting the offer prematurely could undermine the possibility of a superior transaction. Shareholders were instructed to take no action while the strategic review continues.

For investors, the dispute now extends beyond Curaleaf’s headline $5 valuation to the relative financial strength of both companies, the risks embedded in the share-based consideration and whether another bidder will emerge.

As consolidation reshapes the cannabis industry, questions of valuation, balance-sheet strength and shareholder returns are becoming increasingly important. These issues will be central to the conversation at IgniteIt’s Capital & Policy Summit in Washington, D.C., on November 18, where industry executives, investors and policymakers will examine the financial and regulatory forces shaping the sector’s next chapter.